LBRX
LB Pharmaceuticals Inc
44.71
-0.23 (-0.51%)
52w low 14.40
50.16 high
84.8% of range
Open
45.21
High
45.46
Low
44.30
Prev Close
44.94
Volume
341.76K
Avg Vol 3M
360.27K
Market Cap
1.45B
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | 27 |
| Web | site ↗ |
Performance
1D
-0.51%
5D
+9.45%
1M
+24.44%
3M
-1.48%
6M
+38.38%
YTD
+100.85%
1Y
+179.79%
2Y
--
3Y
--
5Y
--
MAX
+183.15%
Valuation
| P/E Trailing | -- |
| P/E Forward | -7.77x |
| Price / Book | 3.45x |
| Price / Sales | -- |
| EV / EBITDA | -7.09x |
| EPS Trailing | -1.12 |
| Dividend Yield | 0.00% |
| Beta | -- |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -38.80% |
| Return on Assets | -24.11% |
| Revenue Growth | -- |
| Debt / Equity | 0.01x |
| Current Ratio | 14.78x |
Business
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.